+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Drugs for the Treatment of Refractory Gout Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Drugs for the Treatment of Refractory Gout Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Drugs for the Treatment of Refractory Gout Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 181 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6081639
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Refractory Gout: An Evolving Therapeutic Frontier

Refractory gout represents a critical juncture in rheumatology, characterized by persistent hyperuricemia and frequent flares despite standard therapies. Patients who fail to respond to first- and second-line treatments face heightened pain, joint damage, and impaired quality of life, underscoring an urgent need for innovative interventions. Recent advances in molecular biology and immunology have yielded novel candidates targeting interleukin pathways, urate transporters, and xanthine oxidase, reshaping therapeutic paradigms. At the same time, traditional approaches continue to play a complementary role in acute flare management. This executive summary distills the most salient developments in drug classes, regulatory shifts, and market dynamics that define the refractory gout landscape today. By synthesizing segmentation analyses, tariff impacts, regional nuances, and company strategies, this overview equips decision-makers with a clear understanding of emerging opportunities and persistent challenges. The subsequent sections provide in-depth insights into transformative shifts, policy influences, and actionable recommendations designed to guide stakeholders toward optimized patient outcomes and sustainable growth in this high-need arena.

Transformative Shifts Redefining Refractory Gout Management

Over the past five years, refractory gout management has undergone profound transformation. Biological therapies have moved from concept to clinic, with fusion proteins and monoclonal antibodies demonstrating potent interleukin-1 inhibition and durable urate reduction. Concurrently, small molecule innovators have refined non-steroidal anti-inflammatory drugs and urate-lowering therapies to enhance selectivity and safety. Regulatory agencies have adopted adaptive pathways, expediting approvals for breakthrough-designated agents and encouraging real-world evidence integration. Strategic partnerships between research institutes and pharmaceutical leaders are accelerating pipeline velocity, while digital health platforms support patient adherence and remote monitoring. These shifts have galvanized investment into novel mechanisms of action, including urate transporter inhibitors and xanthine oxidase blockers, fostering a more personalized approach. Traditional therapies, such as colchicine and corticosteroids, remain pivotal for acute flare relief, yet their role is increasingly viewed through a complementary lens alongside advanced modalities. In sum, the therapeutic landscape is evolving toward precision interventions that address the multifaceted pathophysiology of refractory gout, offering new hope to patients and catalyzing growth opportunities for innovators.

Navigating 2025 U.S. Tariff Implications on Drug Access and Costs

The introduction of the United States’ 2025 tariff adjustments has introduced complexity into drug procurement and pricing strategies. Increased duties on imported active pharmaceutical ingredients have challenged biologics producers, who rely on specialized excipients and manufacturing equipment sourced globally. Small molecule developers face elevated costs for raw materials, particularly for interleukin inhibitors and xanthine oxidase inhibitors manufactured overseas. In response, several companies have accelerated localization of supply chains, forging alliances with domestic contract manufacturing organizations to mitigate duties and maintain margins. Distribution channels, including hospitals, clinics, and online pharmacies, are adjusting inventory models to anticipate longer replenishment cycles and recalibrate pricing structures. Furthermore, end-users in research institutes are reevaluating reagent sourcing strategies to balance budget constraints with experimental continuity. Amid these pressures, agile players are leveraging tariff exclusions and invoking free trade agreements to secure cost relief. Overall, the 2025 tariff landscape demands proactive supply chain diversification and contract realignment, underscoring the importance of resilient procurement frameworks for stakeholders committed to uninterrupted patient access.

Key Insights from Market Segmentation Analyses

A multifaceted segmentation framework illuminates the distribution of therapeutic modalities and stakeholder engagement. Based on drug types, the field is divided into biologics encompassing fusion proteins and monoclonal antibodies, small molecules spanning interleukin inhibitors, non-steroidal anti-inflammatory drugs, and urate-lowering therapies, plus traditional agents such as colchicine and corticosteroids. When considering route of administration, treatments are delivered intramuscularly, intravenously, orally, or subcutaneously to optimize patient convenience and pharmacokinetics. End users range from outpatient and specialty clinics to private and public hospitals, alongside research institutes and emerging online pharmacies that are reshaping distribution. Age group segmentation distinguishes adults aged 18 to 64-which itself splits into young adults (18-35) and middle-age adults (36-55)-from geriatric patients aged 65 and above, reflecting divergent safety and efficacy profiles. Mechanism of action insights highlight IL-1 inhibitors, urate transporter inhibitors, and xanthine oxidase inhibitors as the primary biochemical levers. Finally, patient type segmentation differentiates acute gout flares from chronic refractory gout, underscoring the need for rapid-onset therapies alongside long-term maintenance strategies. Together, these lenses reveal targeted opportunities for formulary positioning, clinical trial design, and marketing tactics tailored to distinct patient journeys.

Regional Dynamics Shaping Refractory Gout Treatment

Regional dynamics play a pivotal role in shaping investment priorities and access pathways. In the Americas, private-public hospital networks and outpatient clinics drive early adoption of innovative biologics, supported by robust reimbursement frameworks and a strong pipeline of small molecule therapies. Europe, the Middle East & Africa exhibit a heterogeneous landscape; Western Europe’s centralized health technology assessments contrast with emerging markets’ focus on cost-effective traditional therapies and generics, while the Gulf Cooperation Council countries invest heavily in novel mechanisms of action to reduce disease burden. In Asia-Pacific, demographic shifts and aging populations in Japan, Australia, and South Korea elevate demand for both acute and chronic refractory gout solutions, whereas rapid urbanization in Southeast Asia fosters growth of online pharmacy channels and telemedicine services. These regional nuances demand localized strategies in clinical development, pricing negotiations, and stakeholder engagement to ensure that cutting-edge treatments reach the patients who need them most.

Competitive Landscape and Leading Innovators

Market leadership hinges on innovation, portfolio breadth, and strategic partnerships. AbbVie Inc. continues to explore monoclonal antibody enhancements, while Ardea Biosciences, Inc. focuses on next-generation urate transporter inhibitors. AstraZeneca plc and Boehringer Ingelheim International GmbH leverage strong small molecule pipelines targeting xanthine oxidase, as Chugai Pharmaceutical Co., Ltd. advances fusion protein candidates. CymaBay Therapeutics, Inc. and Horizon Therapeutics plc prioritize IL-1 blockade with an emphasis on patient-reported outcomes. Ipsen Group and Ironwood Pharmaceuticals, Inc. diversify through novel delivery systems, and Janssen Pharmaceuticals, Inc. partners with research institutes to generate real-world evidence. Novartis International AG integrates digital health tools to support subcutaneous administration, while Regeneron Pharmaceuticals, Inc. refines monoclonal antibody dosing regimens. Sobi, Inc. expands global reach via specialty clinic alliances, and Takeda Pharmaceutical Company Limited enhances its brand through broad age group studies. Meanwhile, Savient Pharmaceuticals, Inc. (now part of Crealta Pharmaceuticals) leverages its acute flare expertise to complement chronic refractory portfolios. Collectively, these players drive competition and collaboration across biologics, small molecules, and complementary technologies.

Actionable Recommendations to Drive Strategic Advantage

Industry leaders should prioritize the following strategic initiatives to secure competitive advantage. First, align research and development pipelines with differentiated mechanisms of action, emphasizing IL-1 and urate transporter inhibitors to address treatment gaps in chronic refractory gout. Second, diversify supply chains by establishing local manufacturing partnerships and pursuing tariff exemptions to safeguard margins against geopolitical fluctuations. Third, deploy adaptive clinical trial designs that incorporate patient stratification by age group and end-user setting, accelerating time-to-approval and refining safety profiles. Fourth, enhance digital engagement by integrating telemedicine platforms, online pharmacy collaborations, and remote adherence monitoring, thereby improving patient retention across outpatient and specialty clinics. Fifth, tailor regional market access strategies by engaging health technology assessment bodies in Europe, leveraging reimbursement corridors in the Americas, and navigating evolving regulatory landscapes in Asia-Pacific. Finally, foster cross-sector alliances between pharmaceutical companies, research institutes, and healthcare providers to co-create real-world evidence streams that bolster product differentiation and payer value articulation.

Conclusion: Advancing Refractory Gout Solutions

In conclusion, refractory gout treatment is entering a period of unprecedented innovation underpinned by next-generation biologics, precision small molecules, and optimized traditional therapies. The 2025 U.S. tariff adjustments and shifting regional landscapes underscore the imperative for agile supply chains and localized market strategies. Comprehensive segmentation insights reveal nuanced opportunities across drug types, administration routes, end-user settings, age groups, mechanisms of action, and patient types, guiding targeted R&D and commercialization efforts. Leading companies are driving competitive dynamics through diversified pipelines, strategic collaborations, and digital health integrations. By adopting the actionable recommendations outlined herein-ranging from adaptive trial designs to supply chain resilience-stakeholders can enhance patient outcomes, mitigate policy headwinds, and secure sustainable growth in this high-need therapeutic area.

Market Segmentation & Coverage

This research report categorizes the Drugs for the Treatment of Refractory Gout Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Biologics
    • Fusion Proteins
    • Monoclonal Antibodies
  • Small Molecules
    • Interleukin Inhibitors
    • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • Urate-Lowering Therapies
  • Traditional Therapies
    • Colchicine
    • Corticosteroids
  • Intramuscular
  • Intravenous
  • Oral
  • Subcutaneous
  • Clinics
    • Outpatient Clinics
    • Specialty Clinics
  • Hospitals
    • Private Hospitals
    • Public Hospitals
  • Online Pharmacies
  • Research Institutes
  • Adults (18-64)
    • Middle Age Adults (36-55)
    • Young Adults (18-35)
  • Geriatric (65+)
  • IL-1 Inhibitors
  • Urate Transporter Inhibitors
  • Xanthine Oxidase Inhibitors
  • Acute Gout Flares
  • Chronic Refractory Gout

This research report categorizes the Drugs for the Treatment of Refractory Gout Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Drugs for the Treatment of Refractory Gout Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • Ardea Biosciences, Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • Chugai Pharmaceutical Co., Ltd.
  • CymaBay Therapeutics, Inc.
  • Horizon Therapeutics plc
  • Ipsen Group
  • Ironwood Pharmaceuticals, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Novartis International AG
  • Regeneron Pharmaceuticals, Inc.
  • Savient Pharmaceuticals, Inc. (Acquired by Crealta Pharmaceuticals)
  • Sobi, Inc.
  • Takeda Pharmaceutical Company Limited

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Drugs for the Treatment of Refractory Gout Market, by Drug Types
8.1. Introduction
8.2. Biologics
8.2.1. Fusion Proteins
8.2.2. Monoclonal Antibodies
8.3. Small Molecules
8.3.1. Interleukin Inhibitors
8.3.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
8.3.3. Urate-Lowering Therapies
8.4. Traditional Therapies
8.4.1. Colchicine
8.4.2. Corticosteroids
9. Drugs for the Treatment of Refractory Gout Market, by Route of Administration
9.1. Introduction
9.2. Intramuscular
9.3. Intravenous
9.4. Oral
9.5. Subcutaneous
10. Drugs for the Treatment of Refractory Gout Market, by End Users
10.1. Introduction
10.2. Clinics
10.2.1. Outpatient Clinics
10.2.2. Specialty Clinics
10.3. Hospitals
10.3.1. Private Hospitals
10.3.2. Public Hospitals
10.4. Online Pharmacies
10.5. Research Institutes
11. Drugs for the Treatment of Refractory Gout Market, by Age Group
11.1. Introduction
11.2. Adults (18-64)
11.2.1. Middle Age Adults (36-55)
11.2.2. Young Adults (18-35)
11.3. Geriatric (65+)
12. Drugs for the Treatment of Refractory Gout Market, by Mechanism of Action
12.1. Introduction
12.2. IL-1 Inhibitors
12.3. Urate Transporter Inhibitors
12.4. Xanthine Oxidase Inhibitors
13. Drugs for the Treatment of Refractory Gout Market, by Patient Type
13.1. Introduction
13.2. Acute Gout Flares
13.3. Chronic Refractory Gout
14. Americas Drugs for the Treatment of Refractory Gout Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Drugs for the Treatment of Refractory Gout Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Drugs for the Treatment of Refractory Gout Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie Inc.
17.3.2. Ardea Biosciences, Inc.
17.3.3. AstraZeneca plc
17.3.4. Boehringer Ingelheim International GmbH
17.3.5. Chugai Pharmaceutical Co., Ltd.
17.3.6. CymaBay Therapeutics, Inc.
17.3.7. Horizon Therapeutics plc
17.3.8. Ipsen Group
17.3.9. Ironwood Pharmaceuticals, Inc.
17.3.10. Janssen Pharmaceuticals, Inc.
17.3.11. Novartis International AG
17.3.12. Regeneron Pharmaceuticals, Inc.
17.3.13. Savient Pharmaceuticals, Inc. (Acquired by Crealta Pharmaceuticals)
17.3.14. Sobi, Inc.
17.3.15. Takeda Pharmaceutical Company Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET MULTI-CURRENCY
FIGURE 2. DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET MULTI-LANGUAGE
FIGURE 3. DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URATE-LOWERING THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COLCHICINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MIDDLE AGE ADULTS (36-55), BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY YOUNG ADULTS (18-35), BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY GERIATRIC (65+), BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY IL-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URATE TRANSPORTER INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ACUTE GOUT FLARES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CHRONIC REFRACTORY GOUT, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 59. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 84. BRAZIL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 86. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 87. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 88. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 89. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 90. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 92. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 93. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 94. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 95. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 96. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 97. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 98. MEXICO DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 99. MEXICO DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 100. MEXICO DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 101. MEXICO DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 102. MEXICO DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. MEXICO DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 104. MEXICO DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 105. MEXICO DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 106. MEXICO DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 107. MEXICO DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 108. MEXICO DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 109. MEXICO DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 124. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 126. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 127. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 129. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 130. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 132. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 133. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 134. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 136. AUSTRALIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 137. AUSTRALIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 138. AUSTRALIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 139. AUSTRALIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 140. AUSTRALIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. AUSTRALIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 142. AUSTRALIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 143. AUSTRALIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 144. AUSTRALIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 145. AUSTRALIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 146. AUSTRALIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 147. AUSTRALIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 148. CHINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 149. CHINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 150. CHINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 151. CHINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 152. CHINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. CHINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 154. CHINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 155. CHINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 156. CHINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 157. CHINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 158. CHINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 159. CHINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 160. INDIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 161. INDIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 162. INDIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 163. INDIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 164. INDIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. INDIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 166. INDIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 167. INDIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 168. INDIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 169. INDIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 170. INDIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 171. INDIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 172. INDONESIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 173. INDONESIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 174. INDONESIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 175. INDONESIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 176. INDONESIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. INDONESIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 178. INDONESIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 179. INDONESIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 180. INDONESIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 181. INDONESIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 182. INDONESIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 183. INDONESIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 184. JAPAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 185. JAPAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 186. JAPAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 187. JAPAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 188. JAPAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. JAPAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 190. JAPAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 191. JAPAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 192. JAPAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 193. JAPAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 194. JAPAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 195. JAPAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 196. MALAYSIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 197. MALAYSIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 198. MALAYSIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 199. MALAYSIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 200. MALAYSIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. MALAYSIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 202. MALAYSIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 203. MALAYSIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 204. MALAYSIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 205. MALAYSIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 206. MALAYSIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 207. MALAYSIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 208. PHILIPPINES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 209. PHILIPPINES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 210. PHILIPPINES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 211. PHILIPPINES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 212. PHILIPPINES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 213. PHILIPPINES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 214. PHILIPPINES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 215. PHILIPPINES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 216. PHILIPPINES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 217. PHILIPPINES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 218. PHILIPPINES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 219. PHILIPPINES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 220. SINGAPORE DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 221. SINGAPORE DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 222. SINGAPORE DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 223. SINGAPORE DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 224. SINGAPORE DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. SINGAPORE DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 226. SINGAPORE DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 227. SINGAPORE DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 228. SINGAPORE DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 229. SINGAPORE DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 230. SINGAPORE DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 231. SINGAPORE DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 232. SOUTH KOREA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 233. SOUTH KOREA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 234. SOUTH KOREA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 235. SOUTH KOREA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 236. SOUTH KOREA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. SOUTH KOREA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 238. SOUTH KOREA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 239. SOUTH KOREA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 240. SOUTH KOREA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 241. SOUTH KOREA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 242. SOUTH KOREA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 243. SOUTH KOREA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 244. TAIWAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 245. TAIWAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 246. TAIWAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 247. TAIWAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 248. TAIWAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 249. TAIWAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 250. TAIWAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 251. TAIWAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 252. TAIWAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 253. TAIWAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 254. TAIWAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 255. TAIWAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 256. THAILAND DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 257. THAILAND DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 258. THAILAND DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 259. THAILAND DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 260. THAILAND DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. THAILAND DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 262. THAILAND DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 263. THAILAND DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 264. THAILAND DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 265. THAILAND DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 266. THAILAND DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 267. THAILAND DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 268. VIETNAM DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 269. VIETNAM DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 270. VIETNAM DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 271. VIETNAM DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 272. VIETNAM DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 273. VIETNAM DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 274. VIETNAM DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 275. VIETNAM DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 276. VIETNAM DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 277. VIETNAM DRUGS

Companies Mentioned

  • AbbVie Inc.
  • Ardea Biosciences, Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • Chugai Pharmaceutical Co., Ltd.
  • CymaBay Therapeutics, Inc.
  • Horizon Therapeutics plc
  • Ipsen Group
  • Ironwood Pharmaceuticals, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Novartis International AG
  • Regeneron Pharmaceuticals, Inc.
  • Savient Pharmaceuticals, Inc. (Acquired by Crealta Pharmaceuticals)
  • Sobi, Inc.
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...

Related Topics

Related Reports

Chronic Refractory Gout - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Chronic Refractory Gout - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Chronic Refractory Gout - Pipeline Insight, 2025 - Product Image

Chronic Refractory Gout - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Gout Therapeutics - Global Strategic Business Report - Product Image

Gout Therapeutics - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Drugs for Treating Hyperuricemia Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

Drugs for Treating Hyperuricemia Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 189 Pages
  • Global, United States Global, United States
From
Recombinant Uricase Market by Product Type (Biosimilars of Recombinant Uricase, Non-Pegylated Uricase, Pegylated Uricase), Route Of Administration (Intramuscular, Intravenous, Subcutaneous), Application, End-User - Global Forecast 2025-2030 - Product Image

Recombinant Uricase Market by Product Type (Biosimilars of Recombinant Uricase, Non-Pegylated Uricase, Pegylated Uricase), Route Of Administration (Intramuscular, Intravenous, Subcutaneous), Application, End-User - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.